Description: Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on developing a diverse pipeline of product candidates for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody designed to inhibit the ROR1 receptor that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of CLL and MCL, and TK-216, a small-molecule compound that is designed to inhibit ETS-family oncoproteins, which is being evaluated in a Phase 1 clinical trial alone and in combination with vincristine as a treatment for Ewing sarcoma, a rare pediatric cancer. In addition, Oncternal has a CAR-T product candidate that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors.
Home Page: www.oncternal.com
ONCT Technical Analysis
12230 El Camino Real
San Diego,
CA
92130
United States
Phone:
858 434 1113
Officers
| Name | Title |
|---|---|
| Dr. James B. Breitmeyer M.D., Ph.D. | Pres, CEO & Director |
| Mr. Richard G. Vincent CPA | CFO, Treasurer & Sec. |
| Dr. Salim Yazji M.D. | Chief Medical Officer |
| Dr. Rajesh Krishnan Ph.D. | Chief Technology Officer |
| Dr. Gunnar F. Kaufmann Ph.D. | Chief Scientific Officer |
| Mr. Chase C. Leavitt | Gen. Counsel |
| Mr. Pablo Urbaneja | Sr. VP of Corp. Devel. |
| Dr. Steven Hamburger Ph.D. | Sr. VP of Regulatory Affairs & Quality Assurance |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8794 |
| Price-to-Sales TTM: | 27.6427 |
| IPO Date: | 2004-02-03 |
| Fiscal Year End: | December |
| Full Time Employees: | 26 |